A phase 1 dose-escalation pharmacokinetic and pharmacodynamic study of TG01 tablets in combination with erlotinib in non-small cell lung cancer patients.
Phase of Trial: Phase I
Latest Information Update: 18 Mar 2010
At a glance
- Drugs Apricoxib; Erlotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Tragara Pharmaceuticals
- 18 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Mar 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
- 20 Aug 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov